Search

Your search keyword '"Dacryocystitis drug therapy"' showing total 6 results
Start Over Descriptor "Dacryocystitis drug therapy" Journal japanese journal of antibiotics
6 results on '"Dacryocystitis drug therapy"'

1. [Ophthalmic use of clindamycin-2-phosphate (author's transl)].

Author

Oishi M, Nishizuka K, Motoyama M, and Ogawa T

Subjects
Abscess drug therapy, Acute Disease, Adult, Aged, Animals, Cellulitis drug therapy, Clindamycin metabolism, Clindamycin therapeutic use, Corneal Diseases drug therapy, Corneal Ulcer drug therapy, Dacryocystitis drug therapy, Drug Resistance, Microbial, Endophthalmitis drug therapy, Eye metabolism, Eyelid Diseases drug therapy, Female, Hordeolum drug therapy, Humans, Male, Meibomian Glands, Middle Aged, Orbit, Organophosphorus Compounds, Rabbits, Staphylococcus aureus drug effects, Uveitis, Anterior drug therapy, Clindamycin analogs & derivatives, Eye Diseases drug therapy
Abstract

Bacterial and clinical experiments for ophthalmic use of clindamycin-2-phosphate (CLDM-2-P) were performed and the results were summarized as follows. 1. The distribution of sensitivity for 100 strains of Staphylococcus aureus isolated in 1975 was in the range of less than or equal to 0.19 approximately greater than or equal to 100 mug/ml, and majority of them (96.0%) were in less than or equal to 0.39 mug/ml. 2. The serum concentration by intramuscular injection of 300 mg and 600 mg CLDM-2-P in a single dose respecitvely reached the peak level after 2 hours and decreased gradually until 12 hours in both of them. 3. Ocular penetrations were examined in rabbit eyes. (1) After instillation of 1% CLDM-2-P solution, the aqueous level reached the highest after 1 hour and measurable after 6 hours. (2) After subconjunctival injection of 5 mg/0.5 ml CLDM-2-P, the aqueous level reached the highest after 2 hours and decreased until 6 hours. (3) After intramuscular injection of 100 mg/kg, the aqueous concentration was recognized from 1 to 8 hours, and peak was reached after 1 hour. 1 to 8 hours, and peak was reached after 1 hour. Aqueous-serum ratio in 1 hour was 37.13%. The ocular tissue concentrations at 2 hours showed relatively high levels in both of outer and inner parts of the eye. 4. The intramuscular injection of CLDM-2-P, 300 approximately 1800 mg daily, against suppurative ocular infections revealed excellent effects on cases of external hordeolum, acute chalazion, lid abscess, orbital phlegmone, corneal infiltration, corneal ulcer, and iridocyclitis purulenta. 5. Side effects: Two cases out of 22 cases complained of diarrhoea and bitter taste after injection, and able to be treated continuously by the drug. No abnormal findings in hepatic and renal tests were observed and no servere side effects like allergic reactions were recognized.

Published
1977

2. [Evaluation of amikacin (BB-K8) in ophthalmological field (author's transl)].

Author

Hatano H, Tokuda H, and Kayaba C

Subjects
Abscess drug therapy, Adult, Aged, Aminobutyrates analogs & derivatives, Animals, Aqueous Humor analysis, Bacterial Infections drug therapy, Cellulitis drug therapy, Conjunctiva, Dacryocystitis drug therapy, Endophthalmitis drug therapy, Eyelid Diseases drug therapy, Female, Gentamicins pharmacology, Hordeolum drug therapy, Humans, Injections, Injections, Intramuscular, Kanamycin metabolism, Kanamycin pharmacology, Kanamycin therapeutic use, Keratitis drug therapy, Male, Microbial Sensitivity Tests, Middle Aged, Rabbits, Staphylococcus drug effects, Surgical Wound Infection drug therapy, Tears analysis, Eye Diseases drug therapy, Kanamycin analogs & derivatives
Published
1974

3. [Evaluation of lividomycin in ophthalmology].

Author

Tokuda H, Hatano H, and Kayaba C

Subjects
Adolescent, Adult, Animals, Anti-Bacterial Agents blood, Anti-Bacterial Agents metabolism, Corneal Ulcer drug therapy, Dacryocystitis drug therapy, Eye metabolism, Female, Hordeolum drug therapy, Humans, Male, Middle Aged, Rabbits, Anti-Bacterial Agents therapeutic use, Eye Diseases drug therapy, Staphylococcal Infections drug therapy
Published
1972

4. [Clinical evaluation of clindamycin-2-palmitate for ophthalmic infections of children].

Author

Oishi M, Imai M, Takahashi T, Motoyama M, and Tanaka M

Subjects
Abscess drug therapy, Child, Child, Preschool, Clindamycin adverse effects, Clindamycin pharmacology, Conjunctivitis drug therapy, Corneal Ulcer drug therapy, Dacryocystitis drug therapy, Evaluation Studies as Topic, Eyelid Diseases drug therapy, Female, Hordeolum drug therapy, Humans, Infant, Male, Palmitic Acids, Staphylococcus drug effects, Uveitis, Anterior drug therapy, Clindamycin therapeutic use, Eye Diseases drug therapy, Infections drug therapy
Published
1973

5. [Ophthalmic application of minocycline].

Author

Mikuni M, Oishi M, Suda S, Imai M, and Takahashi T

Subjects
Abscess drug therapy, Administration, Oral, Adult, Aged, Animals, Aqueous Humor metabolism, Child, Cornea metabolism, Dacryocystitis drug therapy, Eye metabolism, Eye Foreign Bodies drug therapy, Eye Injuries drug therapy, Female, Hordeolum drug therapy, Humans, Injections, Male, Microbial Sensitivity Tests, Middle Aged, Rabbits, Staphylococcus drug effects, Tetracycline adverse effects, Tetracycline blood, Tetracycline metabolism, Tetracycline pharmacology, Eye Diseases drug therapy, Tetracycline therapeutic use
Published
1969

6. [Ophthalmic use of lividomycin].

Author

Mikuni M, Oishi M, Imai M, and Takahashi T

Subjects
Adult, Animals, Anti-Bacterial Agents metabolism, Child, Corneal Ulcer drug therapy, Dacryocystitis drug therapy, Drug Synergism, Eye metabolism, Female, Hordeolum drug therapy, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Pseudomonas Infections drug therapy, Rabbits, Anti-Bacterial Agents therapeutic use, Eye Diseases drug therapy, Staphylococcal Infections drug therapy
Published
1972

Catalog

Books, media, physical & digital resources
See catalog results